331 443

Cited 0 times in

Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study

DC Field Value Language
dc.contributor.author김민환-
dc.contributor.author김지예-
dc.contributor.author신성재-
dc.contributor.author이승현-
dc.contributor.author이유미-
dc.contributor.author홍남기-
dc.date.accessioned2022-03-11T06:15:50Z-
dc.date.available2022-03-11T06:15:50Z-
dc.date.issued2022-02-
dc.identifier.issn2212-1366-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188011-
dc.description.abstractAromatase inhibitor treatment in breast cancer is associated with accelerated bone loss and an increased risk of fracture. Bisphosphonates (BPs) are the mainstay treatment of aromatase inhibitor-associated bone loss (AIBL), which might improve femoral bone at key locations prone to fracture. To test this hypothesis, we performed three-dimensional cortical bone mapping based on quantitative computed tomography (QCT) scans in postmenopausal women with early breast cancer who were receiving aromatase inhibitors. Data of subjects who had both baseline and at least one follow-up QCT at Severance Hospital (South Korea) between 2005 and 2015 were analyzed (BP users, n = 93; BP non-users, n = 203). After exclusion of BP users with low medication persistence (proportion of days covered: <50%), BP users and non-users were 1:1 matched (n = 54 for each group) in terms of age, lumbar spine volumetric bone mineral density (LSvBMD), femoral neck areal BMD (FNaBMD), and total hip areal BMD (THaBMD). During a median follow-up of 2.1 years, BP use attenuated bone loss in LSvBMD (+7.2% vs. -3.8%, p < 0.001), FNaBMD (+1.3% vs. -2.7%, p < 0.001), and THaBMD (-0.3% vs. -2.5%, p = 0.024). BP had a protective effect on cortical parameters of femoral bone: estimated cortical thickness (CTh) (+3.3% vs. + 0.1%, p = 0.007) and cortical mass surface density (CMSD, cortical mass per unit surface area was calculated by multiplying cortical BMD with CTh) (+3.4% vs. -0.3%, p < 0.001). CMSD increased by up to 15% at key locations such as the superior part of the femoral neck and greater trochanter. BP prevented the thinning of average CTh of the femoral neck (-1.4% vs. -6.1%, p < 0.001), particularly at the superior anterior quadrant of femoral neck (absolute difference: +12.8% point vs. non-users). Compared to BP non-users, BP users had improved cross-sectional moment of inertia (+4.4% vs. -0.7%, p = 0.001) and less increase in buckling ratio (+1.3% vs. + 7.5%, p < 0.001). In summary, BP use prevented cortical bone deficits observed in AIBL at key locations of the proximal femur.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfJOURNAL OF BONE ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleProtective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorNamki Hong-
dc.contributor.googleauthorSeung Won Burm-
dc.contributor.googleauthorGraham Treece-
dc.contributor.googleauthorJee Ye Kim-
dc.contributor.googleauthorMin Hwan Kim-
dc.contributor.googleauthorSeunghyun Lee-
dc.contributor.googleauthorSungjae Shin-
dc.contributor.googleauthorYumie Rhee-
dc.identifier.doi10.1016/j.jbo.2021.100409-
dc.contributor.localIdA00482-
dc.contributor.localIdA00984-
dc.contributor.localIdA02113-
dc.contributor.localIdA05934-
dc.contributor.localIdA03012-
dc.contributor.localIdA04388-
dc.relation.journalcodeJ04174-
dc.identifier.eissn2212-1374-
dc.identifier.pmid35024328-
dc.subject.keywordAromatase inhibitor-associated bone loss-
dc.subject.keywordBisphosphonates-
dc.subject.keywordBreast cancer-
dc.subject.keywordCortical bone-
dc.subject.keywordProximal femur-
dc.subject.keywordQuantitative computed tomography-
dc.contributor.alternativeNameKim, Min Hwan-
dc.contributor.affiliatedAuthor김민환-
dc.contributor.affiliatedAuthor김지예-
dc.contributor.affiliatedAuthor신성재-
dc.contributor.affiliatedAuthor이승현-
dc.contributor.affiliatedAuthor이유미-
dc.contributor.affiliatedAuthor홍남기-
dc.citation.volume32-
dc.citation.startPage100409-
dc.identifier.bibliographicCitationJOURNAL OF BONE ONCOLOGY, Vol.32 : 100409, 2022-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.